2026-05-20T04:33:30Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/236402024-11-28T19:30:52Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16971

00925njm 22002777a 4500 dc Carbonell, Caterina author Frigola, Joan author Pardo, Nuria author Callejo, Ana author Iranzo, Patricia author Valdivia, Augusto author Priano, Ilaria author Cedrés, Susana author Martinez-Marti, Alex author Navarro, Alejandro author Lenza, Laura author Soleda, Mireia author Gonzalo-Ruiz, Javier author Vivancos, Ana author Sansó, Miriam author Carcereny, Enric author Morán, Teresa author Amat, Ramon author Felip, Enriqueta author 2023-05 Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from this type of treatment. Here, we assessed the value of shallow whole-genome sequencing (sWGS) on plasma samples to monitor ICI benefit. We applied sWGS on cell-free DNA (cfDNA) extracted from plasma samples of 45 patients with metastatic NSCLC treated with ICIs. Over 150 samples were obtained before ICI treatment initiation and at several time points throughout treatment. From sWGS data, we computed the tumor fraction (TFx) and somatic copy number alteration (SCNA) burden and associated them with ICI benefit and clinical features. TFx at baseline correlated with metastatic lesions at the bone and the liver, and high TFx (≥ 10%) associated with ICI benefit. Moreover, its assessment in on-treatment samples was able to better predict clinical efficacy, regardless of the TFx levels at baseline. Finally, for a subset of patients for whom SCNA burden could be computed, increased burden correlated with diminished benefit following ICI treatment. Thus, our data indicate that the analysis of cfDNA by sWGS enables the monitoring of two potential biomarkers-TFx and SCNA burden-of ICI benefit in a cost-effective manner, facilitating multiple serial-sample analyses. Larger cohorts will be needed to establish its clinical potential. Carbonell C, Frigola J, Pardo N, Callejo A, Iranzo P, Valdivia A, et al. Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. Mol Oncol. 2023 Mar 21. 10.1002/1878-0261.13409 1878-0261 Molecular oncology https://hdl.handle.net/20.500.13003/19060 36852704 L2022163998 2-s2.0-85150932787 https://hdl.handle.net/20.500.12105/23640 957180300001 Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC